Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxorubicin liposomal - 2-BBB Medicines

Next Previous
Drug Profile

Doxorubicin liposomal - 2-BBB Medicines

Alternative Names: 2B3-101; 2X-111; Doxorubicin glutathione-pegylated liposome therapeutic - 2-BBB Medicines

Latest Information Update: 03 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator to-BBB technologies
  • Developer 2-BBB Medicines
  • Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
  • Mechanism of Action DNA intercalators; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Brain metastases; Glioma

Most Recent Events

  • 23 May 2024 Allarity Therapeutics has patent protection for the use of DRP® technology in conjunction with doxorubicin in USA and Europe
  • 23 May 2024 Allarity Therapeutics has patents pending for the use of DRP® technology in conjunction with doxorubicin in Australia, Canada, China, Hong Kong, and India
  • 26 Oct 2020 Allarity Therapeutics receives patent allowance from the USPTO for Methods for predicting drug responsiveness in Cancer in the US

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top